Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

Published:2021-08-09 Issue:6 Volume:22 Page:877-889
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Zhao Yan,Zhang Litao,Ding Yangfeng,Tao Xiaohua,Ji Chao,Dong Xiuqin,Lu Jianyun,Wu Liming,Wang Rupeng,Lu Qianjin,Goh Aik Han,Liu Rongjun,Zhang Zhiguo,Zhang Jianzhong

Funder

Reistone Biopharma Co., Ltd.,

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-021-00627-2.pdf

Reference42 articles.

1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51. https://doi.org/10.1016/j.jaad.2013.10.010.

2. Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52.e3. https://doi.org/10.1016/j.anai.2017.09.076.

3. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–8. https://doi.org/10.1016/j.jaci.2013.08.031.